In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier
Open Access
- 1 January 1986
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 29 (1) , 182-183
- https://doi.org/10.1128/aac.29.1.182
Abstract
The in vitro susceptibilities of 83 clinical isolates of Brucella melitensis to seven cephalosporins and a monobactam were determined. Ceftizoxime, ceftriaxone, and cefotaxime were the most effective agents tested, with MICs ranging from 0.25 to 2 micrograms/ml. Moxalactam, cefoperazone, cefuroxime, and ceftazidime showed MICs between 4 and 64 micrograms/ml, with moxalactam being the most active agent in this group. Aztreonam showed poor activity, with MICs higher than 64 micrograms/ml.This publication has 10 references indexed in Scilit:
- Pharmacokinetic profile of ceftriaxone in man.1984
- Treatment of bacterial meningitis with ceftizoximeAntimicrobial Agents and Chemotherapy, 1984
- Comparison of ceftriaxone and traditional therapy of bacterial meningitisAntimicrobial Agents and Chemotherapy, 1984
- Human BrucellosisClinical Infectious Diseases, 1983
- The New Beta-Lactamase-Stable CephalosporinsAnnals of Internal Medicine, 1982
- In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazoleAntimicrobial Agents and Chemotherapy, 1982
- Antibiotic therapy of bacterial meningitis: Lessons we've learnedThe American Journal of Medicine, 1981
- Determination of the In Vitro Sensitivity of Brucella Strains to RifampicinBritish Veterinary Journal, 1976
- In vitro susceptibility of Brucella to various antibiotics.1970
- Protean Manifestations of Nervous System BrucellosisPublished by American Medical Association (AMA) ,1963